1. Introduction {#sec1}
===============

The current standard of treatment for locally advanced rectal cancer, that is, stage cT3-4/Nx or cTx/N1-2 disease, consists of neoadjuvant chemoradiotherapy (NCRT), followed by radical total mesorectal excision (TME) (plus or minus further adjuvant chemotherapy) \[[@B1]\]. A recent published meta-analysis of randomized controlled trials suggested that preoperative chemoradiotherapy improves local control compared with surgery alone or surgery with neoadjuvant radiotherapy \[[@B2]\]. In addition, neoadjuvant therapy may result in complete eradication of all viable tumor cells from the primary tumor site as well as from the regional lymph nodes, representing pathological complete response (pCR) in this setting. Furthermore, complete response to preoperative NCRT is indicative of better long-term outcomes with low rates of local recurrence and distant failure \[[@B3]\].

A few small studies have recently investigated the influence of the length of the interval between NCRT and surgery (NCRT-surgery interval) on morbidity, resectability, and tumor response \[[@B4], [@B5]\]. However, the optimal NCRT-surgery interval that allows for maximal tumor regression is still unknown, and quantitative summarization of the supporting evidence of each time interval is not available. The purpose of this systematic review was, therefore, to examine the impact of the NCRT-surgery interval on the oncological outcome.

2. Material and Methods {#sec2}
=======================

2.1. Data Sources and Searches {#sec2.1}
------------------------------

We searched PubMed, the Cochrane Library, and Embase databases for relevant articles published until February 1, 2015; no lower date limit was applied. The search was limited initially to English publications. Electronic database searches were performed with the Boolean combination \[(Interval OR time OR timing) AND rectal AND (carcinoma OR cancer) AND (Chemoradiotherapy OR Radiotherapy OR radiation OR neoadjuvant)\] in all fields. In addition, the reference lists of included studies and related publications were screened for additional trials.

2.2. Study Selection {#sec2.2}
--------------------

Two authors independently screened each unique record identified by the searches. Clinical trials meeting the following criteria were included in the meta-analysis: (i) the study directly compared pCR rates between patients in whom surgery for rectal cancer was performed at different intervals after NCRT. (ii) Patients were reported to undergo neoadjuvant radiation-based therapy and concurrent chemotherapy before surgery. (iii) The pCR rates were reported according to longer interval (NCRT-surgery interval longer than cutoff point) and shorter interval (NCRT-surgery interval shorter than cutoff point) categories. Studies that defined more than 2 time intervals were also accepted. (iv) The study had to report comparable data on pCR rates after NCRT of each time interval category. We excluded studies that were not published as full reports, such as conference abstracts and letters to editors. In case of multiple publications on the same study, the most recent information was used. Discrepancies in study selection were resolved by consensus.

2.3. Data Extraction and Study Assessment {#sec2.3}
-----------------------------------------

To avoid bias in the data-abstraction process, two authors assessed the quality, extracted the data, and assessed the risk of bias independently. Any discrepancies between the authors were resolved by consensus. Details about the author, publication year, number of patients, treatment information, patient baseline characteristics, definitions of the pCR, pCR rates, and sphincter preservation rates of different groups and prognosis results were extracted from the included studies. When studies compared pCR rates between more than 2 time intervals, data were collected from each group separately. Methodological quality was assessed using Newcastle-Ottawa quality assessment scale.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Rates of pCR was the primary endpoint, and local recurrence rates, distant metastases rates, overall survival rates, and sphincter preservation rates were the secondary endpoints. All statistical analysis was implemented with Review Manager version 5.3 software (Cochrane Collaboration, Denmark). To calculate relative risk (RR), patients of longer interval group were compared only with those of shorter interval in the same clinical trial. RR together with the 95% confidence interval (CI) was used as summary statistics for dichotomous data. We explored a relationship between pCR rates and time intervals by dividing patients into six categories based on NCRT-surgery intervals. We assessed statistical heterogeneity with *I* ^2^ statistics. Statistical heterogeneity between groups was considered relevant for comparisons with *I* ^2^ statistics of \>50%. The *Z*-test for overall effect and its two-sided *P* value were assessed. Significant difference was considered to be present for *P* \< 0.05.

2.5. Assessment of Bias Risk of the Included Studies and Sensitivity Analysis {#sec2.5}
-----------------------------------------------------------------------------

Publication bias was not evaluated because of the small number of studies included in each subgroup. Sensitivity analysis was performed for studies with same definition of pCR.

3. Results {#sec3}
==========

Our search yielded a total of 3053 potentially relevant clinical studies, of which 2202 were among other themes. We then excluded review articles (*n* = 292), case reports (*n* = 135), comments (*n* = 21), letters (*n* = 18), and articles written in other languages (*n* = 351). In total, 34 articles were retrieved for full-text review. Of these, 6 articles were excluded due to lack of relevant data, 1 due to lack of a control arm, 7 due to failure to define a precise cutoff point of NCRT-surgery interval, and 5 due to failure to report postoperative pathologic outcome. The remaining 15 studies comprised a total of 4431 individuals, which constituted the material for the current review \[[@B6]--[@B20]\] (see [Figure 1](#fig1){ref-type="fig"} for the selection process of these studies).

3.1. Characteristics of Studies Included in the Meta-Analysis {#sec3.1}
-------------------------------------------------------------

Fifteen retrospective cohort studies were included \[[@B6]--[@B20]\]. The studies included in this review are heterogeneous in the time intervals that they compared, ranging from ≤5 weeks versus \>5 weeks to ≤12 weeks versus \>12 weeks. All of the studies reported on patients who received NCRT. Although the exact nature of preoperative radiotherapy differed between the studies examined in this review, the majority of studies administered 45 to 50.4 Gy delivered over a period of 5 to 6 weeks. All of the studies reported on patients who received 5-fluorouracil- (FU-) based chemotherapy, though the chemotherapy regimens used varied. The common factors influencing NCRT-surgery intervals reported by most studies were surgeons\' policy regarding the timing of operation, bed availability on the surgical wards, and comorbidities. The precise definition of complete pathological response was consistent among included studies, except Fang et al. \[[@B16]\] who defined pCR as "pT0 and any pN," and one patient who had a lymph node metastasis (ypT0N2) was therefore included in pCR group. Tulchinsky et al. \[[@B9]\] pooled pCR rates and near-pCR rates together for the analyses. The average methodological quality score was 6.7 (minimum 5, maximum 7) ([Table 1](#tab1){ref-type="table"}).

The clinicopathologic data of the study populations are summarized in [Table 2](#tab2){ref-type="table"}. No differences in average height of tumors from the anal verge were identified between shorter and longer intervals in any of the studies, except Sirohi et al. \[[@B20]\] who reported that height of tumors from the anal verge in shorter interval group was higher (6 cm versus 4 cm; *P* = 0.045). The majority of studies reported that neoadjuvant therapy was given to all patients with stage II or stage III rectal cancer, or with tumors that threatened circumferential resection margin. None of the included studies reported a significant difference in distribution of clinical T-stage and N-stage between shorter and longer intervals cohorts.

3.2. Complete Pathological Response {#sec3.2}
-----------------------------------

Four studies reported a significantly increased rate of pCR after neoadjuvant therapy when patients were operated on at an interval \>7 weeks \[[@B9], [@B13], [@B18], [@B19]\], and de Campos-Lobato et al. \[[@B11]\] found that a waiting interval of ≥8 weeks was associated with a higher rate of pCR. The highest pCR rates were observed in patients undergoing surgery on 10 to 11 weeks after the end of NCRT in the large series reported by Sloothaak et al. \[[@B14]\]. Seven studies reported an insignificant trend toward increased pCR rates in longer interval group \[[@B6]--[@B8], [@B12], [@B15], [@B17], [@B20]\]. No increase in rates of complete response was identified in 2 studies \[[@B10], [@B16]\].

3.3. Meta-Analysis of pCR Rate {#sec3.3}
------------------------------

The reported pCR rates ranged from 8.3% to 28.0% \[[@B6]--[@B20]\]. In order to determine the particular contribution of time intervals of NCRT-surgery to the occurrence of pCR, a meta-analysis was performed to calculate the RR associated with longer time intervals at beyond 5, 6, 7, 8, 10, or 12 weeks when compared to shorter intervals ([Table 3](#tab3){ref-type="table"}, Figures [2](#fig2){ref-type="fig"} [](#fig3){ref-type="fig"} [](#fig4){ref-type="fig"}--[5](#fig5){ref-type="fig"}). No heterogeneity was found among these studies included in the analysis (*I* ^2^ \< 50% each). Using a fixed-effect model, there was a significantly increased rate of pCR in patients treated with surgery followed 7 or 8 weeks later (RR, 1.45; 95% CI, 1.18--1.78; and *P* \< 0.01 and RR, 1.49; 95% CI, 1.15--1.92; and *P* = 0.002). No significant differences were found between shorter and longer intervals cohorts with respect to rate of pCR in earlier cutoff points of 5 and 6 weeks (RR, 0.67; 95% CI, 0.40--1.12; and *P* = 0.13 and RR, 1.03; 95% CI, 0.76--1.42; and *P* = 0.83), and further extension beyond 10 or 12 weeks did not offer further advantages in increasing pCR rates (RR, 0.83; 95% CI, 0.65--1.06; and *P* = 0.13 and RR, 0.81; 95% CI, 0.60--1.08; and *P* = 0.15). Sensitivity analyses excluding data from Tulchinsky et al. \[[@B9]\] to control for patient with near-pCR did not alter the results substantially (RR, 1.39; 95% CI, 1.12 to 1.73; and *P* = 0.003). Data from Fang et al. \[[@B16]\] was also excluded for sensitivity analyses because of different definition of pCR, and result showed no change (RR, 1.09; 95% CI, 0.78 to 1.52; and *P* = 0.61).

We then plotted the pooled RR and 95% CI of pCR rates of different intervals in a line chart. The highest summary point estimate in the RR of pCR rates was observed in patients receiving surgery beyond 8 weeks after the end of NCRT, which was associated with an approximately 49% higher chance of achieving pCR than patients who were operated on less than 8 weeks after the end of NCRT. The corresponding figure for ≥7 weeks\' cutoff point was 45% ([Figure 6](#fig6){ref-type="fig"}).

3.4. Sphincter Preservation {#sec3.4}
---------------------------

Thirteen of the included studies reported rate of sphincter preservation ([Table 4](#tab4){ref-type="table"}). None of the included studies reported a significant increase in rates of sphincter preservation with a longer interval. Habr-Gama et al. \[[@B10]\] reported a lower rate of sphincter preservation among patients undergoing surgery after a longer interval of \>12 weeks, as patients in this study with a suspected cCR after NCRT were enrolled in a watch-and-wait protocol and were not managed by surgery until recurrence occurred.

3.5. Long-Term Outcome {#sec3.5}
----------------------

Twelve of the included studies reported long-term outcomes ([Table 4](#tab4){ref-type="table"}). Six of these found no significant difference in local recurrence rates, or local control rate, and distant metastases rate between patients who were operated on after shorter or longer intervals. A significantly higher rate of local recurrence was reported in patients undergoing surgery after a shorter interval (\<7, 8 weeks) reported by de Campos-Lobato et al. \[[@B11]\] and Zeng et al. \[[@B18]\] (10.5% versus 1.2%, *P* = 0.04, and 12.9% versus 4.8%, *P* = 0.025, resp.). Tulchinsky et al. \[[@B9]\] reported a significant increase in distant metastases rate when surgery was performed after a shorter interval \<7 weeks (19% versus 6%, *P* = 0.02). A significantly higher 5-year free-from-recurrence rate was reported in patients undergoing surgery after an interval of \>8 weeks reported by Wolthuis et al. \[[@B13]\] (73% versus 83%, *P* = 0.026). In terms of overall survival, six studies found no significant difference between patients who were operated on after shorter or longer intervals except 1 study, in which Calvo et al. \[[@B17]\] identified a significant association between increased 5-year overall survival with prolonged interval of ≥6 weeks.

4. Discussion {#sec4}
=============

The optimal timing for surgery after neoadjuvant treatment for rectal cancer remains at large. The justification for an effort to examine optimal timing of surgery after preoperative radiation therapy stems from the Lyon R90-01 study \[[@B21]\], the only randomized trial to date that examines the time interval to surgery, in which outcomes after short (less than 2 weeks) and long (6--8 weeks) intervals following preoperative radiotherapy were compared. The longer interval was correlated with a significantly higher proportion of pathologic downstaging. Furthermore, this trial was the only one that demonstrated an increase of sphincter preservation following longer interval to surgery. Therefore, the 6--8-week interval between NCRT and surgery has become routine practice for rectal cancer. However, patients in this study received a currently unusual radiation dose (39 Gy in 13 fractions), did not routinely undergo TME, and did not receive preoperative chemotherapy. Furthermore, higher safe dose of radiation therapy (3 Gy per fraction) might impact the rate of sphincter preservation. Another ongoing multicentric randomized controlled trial (the GRECCAR6 study) only compares 7 and 11 weeks of delay between the end of NRCT and surgery of rectal cancer \[[@B22]\]. There is no previous studies evaluated the association between each time interval and rate of pCR.

Tumor regression and radiation-induced necrosis are a time-dependent phenomenon \[[@B23]\]. The effects of chemoradiotherapy are based on the cell cycle, and oftentimes multiple cycles administered over the course of several months are necessary before effects are seen \[[@B24]\]. Therefore, there is enthusiasm for prolonging the currently accepted interval of 6--8 weeks in order to maximize the downstaging effect of NCRT and subsequently increase the pCR rate \[[@B25]\]. But will a longer interval even result in a superior rate of pCR? Dolinsky et al. \[[@B26]\] reported the rates of primary tumor downstaging were 42%, 58%, and 71% for patients with intervals of \<6, 6--8, and \>8 weeks, respectively, but an increase in the time interval did not affect the likelihood of achieving a pCR (OR 0.97, 95% CI, 0.78--1.21, and *P* = 0.8) in multivariate analysis. For short-course radiotherapy, there are 4 phase-III studies in the literature with randomized intervals. Two of these studies compared short-course radiotherapy and immediate surgery with short-course radiotherapy and delayed surgery and found that the ypCR rate was about 10% higher in the delayed-surgery group \[[@B27], [@B28]\]. The comparison of short-course radiotherapy and delayed surgery with long-course chemoradiation in another randomized study revealed that the pCR rate was higher in the long-course chemoradiation groups \[[@B29]\]. An interim analysis of a multicentre randomized study that compared short-course radiotherapy and consolidation chemotherapy with long-course chemoradiation revealed a higher pCR rate in the short-course radiotherapy group \[[@B30]\].

A published meta-analysis demonstrated that a longer waiting interval (more than 6--8 weeks) from the end of NCRT increases the rate of pCR by 6% (RR = 1.42, 95% CI, 1.19--1.68, and *P* \< 0.0001), with similar long-term outcomes and complication rates \[[@B31]\]. However, they failed to perform subgroup analysis according to each particular time point. As there was lack of consistency in the time intervals examined by the included studies, heterogeneity may well exist when data of all time intervals were pooled together. After including more trials (including 4 new published trials with 969 patients), we pooled data from different time intervals to perform a subgroup analysis. The present data demonstrated that delaying surgery until the seventh or eighth week after NCRT significantly increased rate of pCR in patients with rectal cancer (increasing rate by 49% and 45%, resp.). Notably, no significant improvement of pCR rate was found when patients had operation beyond commonly accepted 6 weeks, as 6-week point is probably insufficient to reveal relevant differences. Thus, we establish the optimal window between 7-8 weeks to intervene surgically within the established 6--8 weeks\' window.

There is, however, less data published regarding the results of increasing the interval prior to surgical intervention (\>10 weeks). Our data suggests that no significant difference in pCR rate was found when patients had a waiting interval of ≥10 or 12 weeks. However, a potential limitation in our meta-analysis is that only two studies were included in these longer interval subgroups. Garcia-Aguilar et al. \[[@B23]\] indicated that patients operated on 11\~13 weeks after NCRT had a pCR rate of 25%, compared to 18% for patients operated on 6\~8 weeks after NCRT (*P* = 0.022). However, Stein et al. \[[@B24]\] did not find increased rate of pCR when surgery was performed at 10 to 14 weeks (14%) in comparison with surgery at 4 to 8 weeks (21%) after NCRT. In a recent published exploratory phase-2 trial, Garcia-Aguilar et al. \[[@B32]\] showed that adding up to six cycles of mFOLFOX6 chemotherapy between NCRT and surgery, meanwhile, delaying surgery after NCRT, increased the pCR rate. The increased number of cycles was significantly associated with an increased proportion of patients who achieved a pCR. The patients assigned to receive six cycles of mFOLFOX6 after chemoradiation with surgery 19 weeks after NCRT achieved a highest rate of pCR of 38%, which is one of the highest proportions reported so far for stages II-III rectal cancer. However, the excellent clinical response was probably not due to longer interval but preoperative chemotherapy. In addition, a few issues need to be addressed. Waiting longer clearly benefits those patients that achieve a pCR, but over 20% do not respond to preoperative therapy and, in fact, the primary tumor continues to grow \[[@B33]\]. Another concern of delaying surgery is that longer intervals after preoperative radiation may increase the risk of emergence of distant subclinical tumor, which can grow to a metastasis-yielding volume and lead to the development of distant metastases \[[@B34]\]. Despite several studies reporting promising use of imaging technology to help in monitoring disease response during preoperative treatment, no robust imaging technology has been established for widespread clinical use \[[@B35], [@B36]\]. Based on these concerns, further delaying time interval (\>10 weeks) may be inappropriate.

Tumor response to NCRT has been shown to be a predictor of less propensity for local or distant recurrence and improved survival \[[@B16]\]. Indications of tumor regression include downstaging, downsizing, complete, or nearly complete response. As the definitions of downstaging and downsizing varied widely among studies \[[@B37]\], complete pathological response to neoadjuvant therapy has become a widely measured endpoint in rectal cancer clinical trials \[[@B38]\]. In this study, we chose to define pCR as absence of viable adenocarcinoma cells in the surgical specimen, including primary tumor and lymph nodes. There is marked heterogeneity in reported pCR rates across included studies (8.3%--28.0%), probably due to different neoadjuvant therapy protocols and patients with different stages enrolled in. The sensitivity analyses were performed excluding the study in which patients with pCR (*n* = 26) and near-pCR (*n* = 11) were included \[[@B9]\], and another study in which one patient with pT0N2 stage was included in pCR group \[[@B16]\]. Results of sensitivity analyses suggest our findings were robust.

NCRT was reported to achieve tumor downsizing and downstaging, which might cause an increase in the tumor distance from the anal verge, meanwhile increasing the likelihood of sphincter preservation \[[@B39]\]. However, none of the studies included in this review reported a significant increase in rates of sphincter preservation with a longer interval. Although the longer interval to surgery was associated with a higher pCR rates in 4 phase-III trials regarding short-course radiotherapy, the sphincter preservation rate and long-term outcome were similar \[[@B27]--[@B29], [@B32]\]. When comparing with postoperative chemoradiotherapy, the benefit of sphincter preservation and survival was not confirmed for preoperative chemoradiotherapy by results of the German CAO/ARO/AIO-94 randomized phase-III trial \[[@B40], [@B41]\]. In the phase-II trial by Garcia-Aguilar et al., waiting longer than 19 weeks was not associated with an increase in the proportion of patients who had a sphincter-saving procedure. However, patients with good response who refused to undergo TME but local excision were excluded from analyses \[[@B32]\]. Though longer interval was not demonstrated to increase in conventional sphincter-saving procedure (e.g., anterior resection), it can increase the rate of pCR, meanwhile, increasing the proportion of organ preservation (e.g., local excision \[[@B42]\] or watch-and-wait policy \[[@B43], [@B44]\]) for patients with clinical complete response.

Whether there is an association between time interval and prognosis remains controversial. The meta-analysis performed by Petrelli et al. reported similar long-term outcomes between longer and shorter interval groups, but this meta-analysis redichotomised all of the patients into two groups according to the 6--8 weeks\' interval \[[@B31]\]. In the current review, local control, distant metastasis, and overall survival were reported to be similar between longer and shorter interval in most of included studies, though a few studies reported an association between longer intervals with better long-term outcome. We failed to perform a meta-analysis of survival data of each time interval group to compare prognosis of all of the possible intervals, as data were not available. Further studies investigating this are warranted.

Our study has the following limitations. First, all data were extracted from retrospective studies, but the majority of included studies reported patients with similar baseline demographic and oncologic characteristics in both groups. Tulchinsky et al. \[[@B9]\] reported that patients operated on at an interval \>7 weeks were older at operation (*P* = 0.007), but they were able to show that age at operation was not a predictor for pCR and near-pCR (*P* = 0.57). Moreover, while most analyses were conducted from a retrospective perspective, the data used were collected prospectively in the highly standardized manner; neoadjuvant therapy schedule and our primary outcome of interest, pCR, are all routinely collected and objectively measured, thereby minimizing the problems of missing data and reporting bias. Second, the time intervals after NCRT showed significant heterogeneity among the included studies. As surgeons\' policy regarding the timing of operation was reported to be the most common factor influencing NCRT-surgery intervals by most studies, various potential confounders could have been involved in the choice of interval times for the cases considered. For instance, patients with progressive or stable disease after NCRT might have surgery without further delay after completing NCRT, which caused selection bias. Third, we failed to perform a meta-analysis of survival data of each time interval group. Although time intervals of 7-8 weeks significantly increase chances of achieving pCR in present study, it is unclear whether this translates into long-term clinical benefit.

5. Conclusion {#sec5}
=============

The results of this review demonstrate that performing surgery 7-8 weeks after the end of NCRT significantly increases rates of pCR. Increasing the interval prior to surgical intervention alone has no impact on long-term survival. For candidates of abdominoperineal resection before NCRT, these data support implementation of prolonging interval after NCRT to optimize the chances of pCR and perhaps add to the possibility of ultimate organ preservation. This is best addressed in the context of a randomized control trial.
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###### 

Main characteristics of the studies included in the meta-analysis.

  Trial                                Year   Study period   Interval              Radiotherapy schedule                                                                                                  Chemotherapy schedule                                              Delay reason                                                                                                                                                                              pCR definition                                                                                                                                                      Quality score (out of 9)
  ------------------------------------ ------ -------------- --------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------
  Moore et al. \[[@B6]\]               2004   1980--2002     44 days               50.4 Gy, 46.8 Gy in twenty-six 1.8 Gy fractions                                                                        5-FU/LV or irinotecan                                              NA                                                                                                                                                                                        Tumors that were ypT0N0, or only acellular pools of residual mucin were noted                                                                                       7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Tran et al. \[[@B7]\]                2006   1997--2004     8 weeks               45--50.4 Gy                                                                                                            5-FU                                                               According to the surgeons\' preference and because it was typically influenced by tumor size/bulk and the perceived need for tumor shrinkage for resectability and/or sphincter salvage   NA                                                                                                                                                                  7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Lim et al. \[[@B8]\]                 2008   2002--2006     5, 6, and 7 weeks     50.4 Gy, 45 Gy in twenty-five 1.8 Gy fractions over 5.5 weeks                                                          5-FU/LV or capecitabine or irinotecan/capecitabine                 According to the surgeons\' preference and their policy regarding the timing of operation                                                                                                 NA                                                                                                                                                                  7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Tulchinsky et al. \[[@B9]\]          2008   2000--2006     7 weeks               45--50.4 Gy over 5.5 weeks                                                                                             5-FU                                                               According to bed availability on the surgical ward                                                                                                                                        pCR and near-pCR rates (the latter being defined by the finding of microscopic foci of adenocarcinoma in the rectal wall with no cancer cells in the lymph nodes)   6
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Habr-Gama et al. \[[@B10]\]          2008   1991--2005     12 weeks              50.4 Gy over 6 weeks                                                                                                   5-FU/LV                                                            According to the medical conditions as infections and acute myocardial ischemia, among others; hospital bed and operating room availability; and suspected cCR                            ypT0N0M0                                                                                                                                                            7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  de Campos-Lobato et al. \[[@B11]\]   2011   1997--2007     8 weeks               50.4 Gy                                                                                                                5-FU                                                               Attributed to logistical, scheduling, and clinical factors                                                                                                                                Absence of viable adenocarcinoma cells in the surgical specimen, including primary tumor and lymph nodes                                                            7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Evans et al. \[[@B12]\]              2011   2005--2008     6, 8 weeks            45 to 54 Gy, 1.8 Gy per fraction over 5 to 6 weeks                                                                     5-FU/oxaliplatin or 5-FU/irinotecan or 5FU plus other^a^           Attributed to scheduling and comorbidities                                                                                                                                                NA                                                                                                                                                                  6
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Wolthuis et al. \[[@B13]\]           2012   2000--2009     7 weeks               45 Gy in twenty-five 1.8 Gy fractions                                                                                  5-FU                                                               Attributed to logistical factors, hospital bed availability, and surgeons\' and patients\' scheduling preferences                                                                         Mucous lakes without identifiable carcinoma cells                                                                                                                   7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Sloothaak et al. \[[@B14]\]          2013   2009--2011     8, 10, and 12 weeks   50 Gy in twenty-five 2.0 Gy fractions/20.4 Gy in twenty-eight 1.8 Gy fractions/45 Gy in twenty-five 1.8 Gy fractions   5-FU ± oxaliplatin                                                 NA                                                                                                                                                                                        ypT0N0M0                                                                                                                                                            7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Jeong et al. \[[@B15]\]              2013   2008-2009      8 weeks               50.4 Gy, 45 Gy in twenty-five 1.8 Gy fractions over 5 weeks                                                            5-FU/LV, CPT-11/S-1 (16%), TS-1/irinotecan (12%), or Xeloda (6%)   Attributed to logistics, scheduling, and other clinical factors                                                                                                                           NA                                                                                                                                                                  7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Fang et al. \[[@B16]\]               2013   2004--2010     6 weeks               50.4 Gy in twenty-eight fractions over 5.5 weeks                                                                       5-FU                                                               NA                                                                                                                                                                                        T0 any N                                                                                                                                                            5
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Calvo et al. \[[@B17]\]              2014   1995--2012     6 weeks               50.4 Gy, 45 Gy in twenty-five 1.8 Gy fractions over 5 weeks                                                            5-FU + tegafur/Folfox-4                                            Attributed to logistics, scheduling, surgeon discretion, and other clinical factors                                                                                                       A complete absence of tumor cells in the resected specimen (ypt0) and the resected nodes (ypn0)                                                                     6
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Zeng et al. \[[@B18]\]               2014   2005--2012     7 weeks               50.0 Gy, 2.0 Gy per fraction                                                                                           Capecitabine                                                       Attributed to logistical factors, such as hospital bed availability, surgeons\' and patients\' scheduling preferences                                                                     ypT0N0                                                                                                                                                              7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  You et al. \[[@B19]\]                2015   2004--2012     7 weeks               50.0 Gy, 46 Gy in twenty-three 2.0 Gy fractions, and additional 4 Gy injected into the primary tumour                  Folfox-6 or Xelox                                                  NA                                                                                                                                                                                        No cancer cells in either the primary tumour samples or the retrieved lymph nodes, or mucous lakes without identifiable carcinoma cells                             7
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  Sirohi et al. \[[@B20]\]             2014   2012-2013      60 days               50.0 Gy, 2.0 Gy per fraction                                                                                           Capecitabine                                                       Attributed to a long waiting list for surgery or patients\' scheduling preferences                                                                                                        NA                                                                                                                                                                  7

^a^Other: cetuximab or bevacizumab.

NA, data not available; 5-FU, 5-fluorouracil.

###### 

The clinicopathologic data of the study populations.

  Trial                                Interval    Patient number   Mean age (years)   Gender   Interval range      Height from anal verge, cm   Preneoadjuvant therapy stage   pCR%           pCR (*n*)        *P* value                              
  ------------------------------------ ----------- ---------------- ------------------ -------- ------------------- ---------------------------- ------------------------------ -------------- ---------------- ---------------- ------- ------ ------ -------
  Moore et al. \[[@B6]\]               ≤44 days    82               59                 52       30                  15∼206 days                  6.1                            3              28               51               0       12     10     0.19
  \>44 days                            73          62               46                 27                           6.4                          3                              21             49               0                19      14            
                                                                                                                                                                                                                                                       
  Tran et al. \[[@B7]\]                ≤8 weeks    16               62.3               10       6                   8∼43 weeks                   ≤10 (NS)                       0              8                8                0       6      1      0.19
  \>8 weeks                            32          58.1             18                 14                                                        1                              18             11               1                9       3             
                                                                                                                                                                                                                                                       
  Lim et al. \[[@B8]\]                 2∼41 days   217              55.3               138      79                  35.6 ± 3.3 days              4.8 ± 2.1                                     43 (I + II)      174              0       13.8   30     0.74
  42∼56 days                           180         57.5             125                55       50.1 ± 4.4 days     4.8 ± 2.1                                                   39 (I + II)    141              0                15      27            
                                                                                                                                                                                                                                                       
  Tulchinsky et al. \[[@B9]\]          ≤7 weeks    48               59                 35       13                  13∼173 days                  5.6                            0              39               6                0       16.7   8      0.03
  \>7 weeks                            84          64               54                 30                           6.2                          0                              63             17               0                34.5    29            
                                                                                                                                                                                                                                                       
  Habr-Gama et al. \[[@B10]\]          ≤12 weeks   121              56.9               65       56                  9.8 ± 2.2 weeks              4.1 ± 1.7                      10             50               23               0       13     11     0.2
  \>12 weeks                           129         60               83                 46       25.8 ± 12.3 weeks   3.9 ± 1.8                    7                              57             25               0                8       6             
                                                                                                                                                                                                                                                       
  de Campos-Lobato et al. \[[@B11]\]   \<8 weeks   91               57                 129      48                  4∼14 weeks                   5.5 (4--7)                     0              53               28               0       16.2   13     0.027
  ≥8 weeks                             86                                                                           6 (3--7)                     0                              50             39               0                31.1    28            
                                                                                                                                                                                                                                                       
  Evans et al. \[[@B12]\]              \<6 weeks   18               66                 60       35                  3 days∼24 weeks              NS                             NA^a^          0                27               NA^a^   5.6    1      NA
  6∼8 weeks                            32                                                                                                        NA^a^                          6              23               NA^a^            12.5    4             
  \>8 weeks                            45                                                                                                        NA^a^                          10             34               NA^a^            17.8    8             
                                                                                                                                                                                                                                                       
  Wolthuis et al. \[[@B13]\]           ≤7 weeks    201              64                 124      77                  28∼103 days                  ≤10                            0              27               174              0       15.9   32     0.006
  \>7 weeks                            155         62               109                46       50∼103 days                                      0                              14             141              0                28.4    43            
                                                                                                                                                                                                                                                       
  Sloothaak et al. \[[@B14]\]          \<8 weeks   312              63                 200      112                 1∼80 weeks                   NS                                            74 (I + II)      198 (III + IV)           10.3   32     0.013
  8∼9 weeks                            511         63               327                184                                                                                      105 (I + II)   354 (III + IV)                    13.1    67            
  10∼11 weeks                          406         64               244                162                                                                                      68 (I + II)    306 (III + IV)                    18      73            
  ≥12 weeks                            364         64               229                135                                                                                      68 (I + II)    255 (III + IV)                    11.8    43            
                                                                                                                                                                                                                                                       
  Jeong et al. \[[@B15]\]              \<8 weeks   105              58.4               79       26                  4∼14 weeks                   4.8 ± 2.6                      6              30               69               0       16.2   17     0.817
  ≥8 weeks                             48          56.4             38                 10                           4.7 ± 2.7                    3                              7              38               0                18      9             
                                                                                                                                                                                                                                                       
  Fang et al. \[[@B16]\]               5∼6 weeks   32               NA                 NA       NA                  NA                           mid and low rectal cancer      0              56               50               0       18.8   6      0.372
  ≥6 weeks                             74                                                                                                                                                                                        12.2    9             
                                                                                                                                                                                                                                                       
  Calvo et al. \[[@B17]\]              \<6 weeks   136              65.5               91       45                  4∼8 weeks                    7.0                                           47^a^            84^a^                    8.8    12     0.34
  ≥6 weeks                             199         66.0             109                90                           7.0                                                         45^a^          147^a^                            12.1    24            
                                                                                                                                                                                                                                                       
  Zeng et al. \[[@B18]\]               ≤7 weeks    111              59                 62       49                  25--105 days                 NS                                            32               79                       15.3   17     0.029
  \>7 weeks                            122         59               68                 54                                                        28                             94                              27.1             33                    
                                                                                                                                                                                                                                                       
  You et al. \[[@B19]\]                ≤7 weeks    139              55                 96       43                  4--14 weeks                  NS                                            40               99                       27.3   38     0.030
  \>7 weeks                            152         56               108                44                                                        50                             102                             29.6             45                    
                                                                                                                                                                                                                                                       
  Sirohi et al. \[[@B20]\]             ≤60 days    42               50                 28       14                  6--474 days                  6                                             NA                                14      6      0.24   
  \>60 days                            68          48               50                 18                           4 (*P* = 0.045)                                                                                              24      16            

^a^with data missing.

NA: data not available.

###### 

Meta-analysis of pCR rate according to time intervals.

  Time intervals   Number of studies   Longer time intervals (*n*)/shorter intervals (*n*)    Test for heterogeneity   RR     95% CI   *P* value    
  ---------------- ------------------- ----------------------------------------------------- ------------------------- ------ -------- ------------ --------
  5 weeks          1                   309/88                                                ---                       ---    0.67     0.40--1.12   0.13
  6 weeks          5                   640/448                                               28%                       0.23   1.03     0.76--1.42   0.83
  7 weeks          5                   630/779                                               25%                       0.26   1.45     1.18--1.78   \<0.01
  8 weeks          6                   1568/608                                              0%                        0.92   1.49     1.15--1.92   0.002
  10 weeks         1                   770/543                                               ---                       ---    0.83     0.65--1.06   0.13
  12 weeks         2                   493/1350                                              0%                        0.41   0.81     0.60--1.08   0.15

CI, confidence interval.

###### 

The sphincter-preserving procedure rate and long-term outcome.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                Interval     Sphincter-preserving procedure (%)   *P* value   Median follow-up (months)   Local recurrence                                             Distant metastases                                             Overall survival
  ------------------------------------ ------------ ------------------------------------ ----------- --------------------------- ------------------------------------------------------------ -------------------------------------------------------------- -------------------------------------------
  Moore et al. \[[@B6]\]               ≤44 days     79.3                                 0.54                                    NA                                                                                                                           

  \>44 days                            83.6                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  Tran et al. \[[@B7]\]                ≤8 weeks     75.0                                 1.0         27.7                                                                                     31% versus 34% (*P* = 0.53)                                     

  \>8 weeks                            75.0                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  Lim et al. \[[@B8]\]                 2∼41 days    83.9                                 0.688       31                          Local recurrence-free survival (*P* = 0.1165)                                                                               *P* = 0.8386

  42∼56 days                           82.2                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  Tulchinsky et al. \[[@B9]\]          ≤7 weeks     62.5                                 0.95        35                          6% versus 4% (*P* = 0.67)                                    19% versus 6% (*P* = 0.02)                                      

  \>7 weeks                            61.9         31                                                                                                                                                                                                       

                                                                                                                                                                                                                                                             

  Habr-Gama et al. \[[@B10]\]          ≤12 weeks    52.9                                 0.003       46                          34% versus 30% (*P* = 0.75)                                  12% versus 12% (*P* = 0.999)                                    

  \>12 weeks                           34.1                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  de Campos-Lobato et al. \[[@B11]\]   \<8 weeks    72.3                                 0.86        59                          10.5% versus 1.2% (*P* = 0.04)                               17.7% versus 14.1% (*P* = 0.85)                                85.5% versus 88.2% (*P* = 0.74)

  ≥8 weeks                             72.3                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  Evans et al. \[[@B12]\]              \<6 weeks    83.3                                 NA                                      NA                                                                                                                            

  6∼8 weeks                            84.4                                                                                                                                                                                                                  

  \>8 weeks                            73.3                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  Wolthuis et al. \[[@B13]\]           ≤7 weeks     86.1                                 0.18        4.99 years                  5 years free from recurrence: 73% versus 83% (*P* = 0.026)   5-year cancer related survival: 83% versus 91% (*P* = 0.046)   

  \>7 weeks                            78.7         4.73 years                                                                                                                                                                                               

                                                                                                                                                                                                                                                             

  Sloothaak et al. \[[@B14]\]                       NA                                   NA                                      NA                                                                                                                           

                                                                                                                                                                                                                                                             

  Jeong et al. \[[@B15]\]              \<8 weeks    82.4                                 0.341       38                          3 years: 7.8% versus 12.7% (*P* = 0.279)                     3 years: 24% versus 18.9% (*P* = 0.427)                        3 years: 90.2% versus 87.2% (*P* = 0.825)

  ≥8 weeks                             75                                                                                                                                                                                                                    

                                                                                                                                                                                                                                                             

  Fang et al. \[[@B16]\]               5∼6 weeks    NA                                   NA          32.2                        3.1% versus 10.8% (*P* = 0.147)                              31.3% versus 14.9% (*P* = 0.052)                                 

  ≥6 weeks                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                             

  Calvo et al. \[[@B17]\]              \<6 weeks\   64\                                  0.4         71 \                        5-year local control: 90.4% versus 94.5% (*P* = 0.123)       5 years: 55.9 versus 70.4% (*P* = 0.014)                       
                                       ≥6 weeks     68.3                                                                                                                                                                                                     

                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                             

  Zeng et al. \[[@B18]\]               ≤7 weeks     59.5                                 0.335       42                          3 years: 12.9% versus 4.8% (*P* = 0.025)                     3 years: 14.4% versus 12.6% (*P* = 0.651)                      3 years: 89.0% versus 94.5% (*P* = 0.651)

  \>7 weeks                            65.6                                                                                                                                                                                                                  

                                                                                                                                                                                                                                                             

  You et al. \[[@B19]\]                ≤7 weeks\    55.4\                                0.832       55\                         5-year DFS: 74.7% versus 66.8% (*P* = 0.248)                 5 years: 84.4% versus 75.3% (*P* = 0.679)                      
                                       \>7 weeks    57.2                                             49                                                                                                                                                      

                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                             

  Sirohi et al. \[[@B20]\]             ≤60 days     62                                   0.357       13                          Overall recurrence: 14% versus 21% (*P* = 0.405)                                                                            

  \>60 days                            53                                                                                                                                                                                                                    
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA = data not available.

[^1]: Academic Editor: Ralf-Dieter Hofheinz
